BeiGene is a global biotechnology company that develops and commercializes innovative oncology medicines.

BeiGene

Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2023, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 50% of BeiGene's revenue.

COM:BEIGENE

BeiGene

Last Close

194.56

22/11 21:00

Market Cap

20.24B

Beta: -

Volume Today

222.26K

Avg: -

Analysis Not Available